Author: Mahrukh Rehan

MediWound Ltd. (MDWD) has seen a decline of 18.92% in the aftermarket. However, the last trading session closed at $2.59 with a decrease of 5.82%.

Pediatric Label Extension – What’s up?

On 18^th November 2021, MDWD reported that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given the Company good scientific advice on the pediatric label modification for NexoBrid. The Company plans to file a pediatric label authorization form in the first half of 2022, based on the input.

So what?

The company is overjoyed to have gained cooperation and favorable advice from the CHMP on the regulatory process. Having a non-surgical alternative for these badly burnt young kids will be a huge improvement over the present surgical standard.

NexoBrid has seen significant growth in Europe, and our marketing team and sales partner are excited to extend the market and continue to enhance the standard of care with the prospective pediatric label extension.

Third Quarter 2021 Results by MDWD – How’s the quarter?

MDWD announced third quarter 2021 results on 16^th November 2021. According to the report issues, the overall revenue was $6.4 million, compared to $6.6 million in the same period of 2020. Moreover, the first nine months of 2021 had total revenues of $18.3 million, 21% more than $15.1 million at the same time of 2020. Furthermore, the firm has $13.9 million in cash and short-term investments.

The Company achieved clarity on a route forward for resubmitting its NexoBrid Biologics License Application (BLA). Last but not least, the company also released positive top-line findings for eschar eradication of severe heat burns in phase III pediatric research.

Now what?

MDWD is happy with the success it has achieved across the portfolio this quarter. The company managed to gain regulatory clarity on the NexoBrid BLA resubmission pathway, and it keeps making substantial progress in EscharEx’s clinical development programs.

Moreover, as the company moves close to the year and looks ahead to 2022, they remain positive about its initiatives. Lastly, MDWD is excited to keep the momentum going as they work toward their strategic goals.

Second Quarter 2021 Financial Results by MDWD

MDWD reported second-quarter 2021 results on 10^th August 2021. In the second quarter of 2021, total revenues were $6.1 million, 50% more than the same period in 2020. Moreover, the firm has $17.2 million in cash and short-term investments.

Interim review for the EscharEx U.S. phase II adaptive design trial found no modifications to the study. However, the complete study enrolment is scheduled by the end of 2021, with data readout in the first part of 2022.

Century Therapeutics, Inc. (IPSC) experienced an increase of 6.98% in aftermarket. However, the last trading session closed at $17.2 with a decline of 4.18%.

Piper Sandler 33rd Annual Virtual Healthcare Conference – When is it?

IPSC announced on 22^nd November 2021 that the senior members from management will take part in the Piper Sandler 33rd Annual Virtual Healthcare Conference. The conference will occur from 30^th November –  2^nd December 2021.

Third Quarter Results 2021 by IPSC – What are the new updates?

On 10^th November 2021, IPSC reported third-quarter 2021 results. According to the company, the cash and cash equivalents came out to be $400.3 million. Moreover, the research and development costs were $19.5 million and general and administrative costs were $19.5 million. Lastly, the net loss was $26 million compared to $13.1 million for the same period in 2020.

Now what?

IPSC proceeded to intensify the investment opportunities in cellular reprogramming, genetic engineering, and production. This will be helpful to advance the iPSC platforms. Moreover, this was done with the intention to develop treatments that can substantively advance cancer care.

In addition, as part of the aim to establish a next-generation cell treatment platform, the company is investing in new technologies through the recently announced cooperation with Outpace Bio. Later this year, and at the future virtual research and development update, the company plans to share scientific updates on the initiatives.

Research Collaboration by IPSC – what’s happening?

On 7^th October 2021, IPSC announced the research collaboration in CAR engineering. By merging Outpace’s optimized CAR spacer technology with Century’s VHH domain binders, the cooperation will combine Century’s CAR and protein engineering skills with Outpace’s protein design and synthetic biology capabilities to boost CAR functioning.

As an emerging leader in iPSC-based cell therapy, investing in cutting-edge cell engineering technology is key to developing breakthrough next-generation allogeneic cell therapeutics. In addition, the agreement with Outpace will strengthen the protein engineering skills and may speed up the development of unique next-generation CARs.

What’s Next?

IPSC happily works to generate highly optimized CARs for their promising iPSC-based cell treatments. This cooperation provides the perfect opportunity to speed up the effect of Outpace’s spacer technology. This would be part of the wider strategy to create T cell therapies, and Outpace’s protein design capabilities. Hence, it allows offering improved capabilities and flexibility to Century’s iPSC platform and product candidates.

Nova LifeStyle, Inc. (NVFY) saw a decrease of 9.45% in the aftermarket. However, the last trading session closed at $2.043 with a decrease of 1.4%.

Third Quarter 2021 Results by NVFY – What’s the update?

NVFY announced the third-quarter results on 15^th November 2021. Net sales for the three months ending September 30, 2021, were $2.9 million, 12% down from $3.3 million for the same time in 2020. Moreover, the gross profit was $1.4 million, compared to a $6.6 million loss in the same quarter of 2020. Lastly, the net loss from continuing operations was $1.4 million, compared to an $8.2 million loss.

Now what?

The company successfully secured funds in the third quarter to enhance the position and enable them to carry out a number of activities that we feel would benefit the sales and marketing efforts. Moreover, they also feel that their inventory levels enable them to service incoming orders and expedite client purchase requests quickly and efficiently. Lastly, the reactions they received during the Las Vegas Market Tradeshow in September were likewise quite encouraging.

Second Quarter 2021 Results by NVFY – How’s the quarter?

NVFY reported second-quarter 2021 results on 16^th August 2021. For the three months ending June 30, 2021, net sales were $3.6 million, 55 percent more than $2.3 million at the same time in 2020. Moreover, the gross profit for the period ending June 30, 2021, came out to be $1.5 million. Lastly, the net loss was $6.3 million, compared to $0.5 million in the previous year.

What’s next?

The Company had a solid first half of the year, and this quarter was no exception. The company has been able to grow sales as the Covid pandemic continues to disrupt supply chains. Some of the clients have restarted operations after suspending or drastically reducing operations in reaction to the epidemic. Moreover, NVFY has also been assisting with product delivery. The company is still working with the suppliers and manufacturers to make sure they can meet their customers’ demands when they recover to pre-pandemic levels.

The company is sticking to its business plan, which includes focusing on higher-margin items. This year’s revenues have grown, and NVFY expects a healthy pipeline for the rest of the year. The team feels that the inventory investments and enhancements to the web presence that the company has made since the outbreak have positioned them to assist current customers. Last but not least, NVFY is looking forward to continuing to expand its sales.

Eos Energy Enterprises, Inc. (EOSE) experienced an increase of 12.37% in the premarket. However, the last trading session closed at $9.7 with an incline of 4.86%.

Third Quarter 2021 Results by EOSE

EOSE reported third-quarter 2021 results on 10^th November 2021. The completion of the Motor Oil, River Valley, and ReNew projects brought in $0.7 million in income. Moreover, the cost of goods sold is $12.9 million, which includes expenditures associated with continuing to build up manufacturing capacity.

Not only this but the $5.1 million increase in R&D expenses compared to 2Q21 was due to continued investments in materials and personnel to support Z3 development. Furthermore, staff-related accruals and outside service expenditure drove down selling, general, and administrative expenses to $8.8 million, a $2.5 million decrease from 2Q21. Lastly, the Koch convertible notes accounted for the majority of the $3.7 million in interest expenditure.

How’s the quarter been?

The market for longer-duration energy storage continues to develop, and the advantages of the innovation, such as cheap cost of ownership, scalability, safety, and operational flexibility, have remained popular.

EOSE is continuing to gain traction in the energy business, with orders from Ameresco and a follow-on from Duke Energy. EOSE is very thrilled that their efforts have resulted in the largest order in business history, 300 MWh, from Blue Ridge Power and Pine Gate Renewables.

300MWh Order from Solar EPC Firm Blue Ridge Power – EOSE provides updates!

EOSE announced on 10^th November 2021 that it has made connections with its largest client i.e., Blue Ridge Power. The installation will commence in the summer of 2022 on a property owned by developer Pine Gate Renewables. In 2022 and 2023, Eos will deliver its zinc-powered Znyth technology for a number of projects.

Moreover, EOSE handles the fluctuation of renewable energy sources by supplying stable power to applications. The Znyth battery will supply continuous power once installed. Furthermore, Zynth batteries, which were developed in Edison, New Jersey, and are made of non-rare earth materials, have been proved safe in a wide variety of operating situations and are 100 percent recyclable at the end lives.

Now what?

EOSE is happy to work with Blue Ridge Power on this historic project to bring additional energy storage to the United States. They have scalable and bankable technology and hope to use the initiative as a model. EOSE considers them the real energy storage pioneers who see the financial value, lifespan advantages, and social impact.

SCYNEXIS, Inc. (SCYX) experienced an incline of 2.47% in the premarket. However, the last trading session concluded at $7.69 with an increase of 1.72%.

Phase 3 VANISH-306 Trial Results – What’s up?

SCYX announced on 23^rd November 2021 that the results of its Phase 3 VANISH-306 research have been peer-reviewed and published in the International Journal of Obstetrics and Gynecology (BJOG). Moreover, the VANISH-306 trial found that oral ibrexafungerp therapy was better than placebo on major study endpoints with a significant level of statistical validity, as well as being relatively safe and well-tolerated.

Now what?

The company thinks that the release of the data from VANISH-306 research will offer doctors critical information on the effectiveness and safety of this ground-breaking medicine as a potentially life-saving therapeutic option for millions of women throughout the country.

Third Quarter 2021 Results Disclosed – What’s new?

SCYX reported third-quarter 2021 results on 10^th November 2021. The report says that BREXAFEMME produced $0.5 million in net product revenues, which was in line with internal expectations. Moreover, the cost of product revenues was $0.1 million. The cost of research and development for the three months came out to be $4.4 million.

Furthermore, the selling, general, and administrative expenditure grew to $15.4 million, $3.5 million more than the same period in 2020. Cash and cash equivalents were at $100.1 million, $93.0 million more than that of December 31, 2020. Lastly, SCYX believes that its existing cash and cash equivalents, the sale of a part of its New Jersey NOLs, and the expected sales of BREXAFEMME will enable the company to finance its operational requirements until 2023, based on its current operating plan.

Completion of Phase 1 Trial – Recent Updates by SCYX

SCYX reported the conclusion of Phase 1 clinical trial in healthy volunteers to assess the safety, tolerability, and pharmacokinetics of a liposomal intravenous (IV) formulation of ibrexafungerp on 9^th November 2021. Experts conducted research on 64 healthy volunteers with treatment durations ranging from one to seven days. Moreover, Ibrexafungerp was well tolerated in its liposomal IV formulation, with no significant side effects noted. Mild (with a few moderate) responses at the infusion site were the most prevalent side effects.

Alpha Pro Tech, Ltd. (APT) experienced an incline of 13.28% in the premarket. However, the last trading session concluded at $5.12 with an increase of 2.61%.

Third Quarter 2021 Results by APT

APT reported third-quarter 2021 results on 4^th November 2021. According to the report, the net income for the three months ending September 30, 2021, was $766,000. From $15.1 million in the third quarter of 2020 to $4.9 million in the third quarter of 2021, gross profit dropped by $10.2 million. Moreover, the gross profit margin was 34.1 percent, compared to 50.4 percent for the same period last year.

The Company presently has no debt and believes that its cash balance will be sufficient to meet forecasted working capital needs. Last but not the least, the Company has committed to investing roughly $4.0 million in capital projects to improve manufacturing capacity.

Now what?

In the third quarter, APT continues to see mask and shield sales normalize to pre-pandemic levels, as expected by management. When compared to the third quarter of 2021, the third quarter of 2020 had the highest level of pandemic-related mask and shield sales, resulting in a larger sales reduction.

Because inventory levels in the supply chain were greater than historical levels as a result of record sales in the first and second quarters of 2021. The company stated this assumption in the second-quarter results report, and they think that once their channel partners’ inventory levels return to normal, this will normalize.

Second Quarter 2021 Financial results – Was it strong enough?

APT released second-quarter 2021 financial results on 4^th August 2021. According to the report, the net sales were $17.8 million, 30.2 percent less than the second quarter of 2020. Moreover, sales in the Disposable Protective Apparel sector fell 55.6 percent to $8.0 million in the same period of 2020.

Furthermore, sales in the Building Supply category climbed by $2.3 million to $9.8 million for the three months ended June 30, 2020. Not only this, but the second quarter of 2021 brought in $1.7 million in net income, compared to $6.2 million. Lastly, the company had $15.5 million in cash and $50.1 million in working capital, with no debt.